Navigation Links
The future of interventional cardiology presented at TCT 2008
Date:10/7/2008

ve Randomized Comparison of Zotarolimus-Eluting Stents, Sirolimus-Eluting Stents, and Paclitaxel-Eluting Stents in Patients with Acute Myocardial Infarction
  • PREPARE: A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • ARNO: A Prospective Randomized Trial Comparison of Bivalirudin and Unfractionated Heparin Plus Protamine in Patients Undergoing Elective Percutaneous Coronary Intervention
  • NAPLES: A Prospective Randomized Trial Comparison of Bivalirudin and Unfractionated Heparin Plus Tirofiban in Patients with Diabetes Mellitus Undergoing Elective Percutaneous Coronary Intervention
  • PROBI VIRI: A Prospective Randomized Trial of an Extended Bivalirudin Infusion in Patients Undergoing Percutaneous Coronary Intervention
  • ASSIST: A Prospective Randomized Trial Evaluating Early Eptifibatide Administration in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Thienopyridine Loading
  • FATA: A Prospective Randomized Trial of Tirofiban and Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • HORIZONS-AMI: A Prospective Randomized Trial of Paclitaxel-Eluting Stents vs. Bare-Metal Stents in Patients with Acute ST-Segment Elevation Myocardial Infarction
  • HORIZONS-AMI: A Prospective Randomized Trial of Bivalirudin vs. Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Acute ST-Segment Elevation Myocardial Infarction: Long-Term Follow-Up and Interaction with Stent Type

    THURSDAY, OCTOBER 16, 9:00 A.M.

    • SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
    • BBC ONE: A Prospective Randomized Comparison of a Single Drug-Eluting Stent Provisional Strategy vs. Routine Dual Drug-
      '/>"/>

    Contact: Judy Romero
    jromero@crf.org
    212-851-9311
    Cardiovascular Research Foundation
    Source:Eurekalert

    Page: 1 2 3

    Related medicine news :

    1. Plastic Surgery 2008 to Showcase Future of Plastic Surgery Through Groundbreaking Research
    2. A look to the future
    3. Campaign for Americas Future Co-Director Roger Hickey Available to Discuss the Future of Health Care Under the Obama and McCain Administrations
    4. More Older Americans Seeking Online Resources to Plan for Their Future
    5. Social Security Disability Can Be Key to Financial Future
    6. Florida Hospital Unveils New Details, Name for Childrens Hospital of the Future
    7. New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia
    8. Office of the Future Environment Study
    9. Office of the future environment study
    10. Plexus Consulting Group Works With a USAID-Funded Project to Help the Private Hospitals Association of Jordan Create a Roadmap for the Future
    11. Seeding the future: SNM grants grow molecular imaging and nuclear medicine research
  • Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:11/28/2014)... 27, 2014 (HealthDay News) -- Celebration can quickly ... on Thanksgiving Day, experts say. Over the last ... have occurred while people were using turkey fryers, according ... have actually cared for a patient who tried to ... be done in any circumstances," Dr. Arthur Sanford, a ...
    (Date:11/28/2014)... Not only is the Éminence Organic ... petroleum, parabens and other cancer-causing agents, but they are ... and awareness programs that help in the fight against ... raised an incredible, record-breaking contribution of $30,000 through participation ... the Sweet Red Rose Whip Moisturizer and the company’s ...
    (Date:11/28/2014)... 2014 Earlier in the year, ... hugely popular, 2014 MTV Video Music Awards broadcasted ... ground-breaking celebrity centered television advertisements directed at 11.9 ... were estimated by Entertainment Weekly and ... spotlight on celebrities photographed by paparazzi smoking. In ...
    (Date:11/28/2014)... A newly released article from Community Health Center ... that will soon be spreading across the United States during ... a brief explanation of what the influenza virus is and ... under the age of 5, adults over the age of ... and lung diseases, asthma, or diabetes, are at higher risk ...
    (Date:11/28/2014)... Patten Pecans, based in Lakeland, Georgia, loves ... driving them, they've added a pecan oil to their ... oils, they've found this pecan oil from Oliver ... retaining the buttery pecan notes that are in the ... found in pecans nuts is found in pecan oil, ...
    Breaking Medicine News(10 mins):Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
    ... Carson M.D., professor of medicine and director of the Rebecca ... California, San Diego (UCSD) has identified a potent new anti-cancer ... South Pacific. The properties of somocystinamide A (ScA) are ... Proceedings of the National Academy of Science the week of ...
    ... A University of Alberta study recommends that workers on pig ... a child on a communal farm in Canada was diagnosed ... made a full recovery, health researchers were concerned because of ... multi-family community, who, fortunately, all demonstrated mild or no apparent ...
    ... $1 million, Five-year Grant, from New York State Department ... Becomes Lead,Poisoned, NEW YORK, Feb. 11 The ... at Montefiore,(CHAM) has been named one of three State ... regional healthcare delivery for children and,pregnant women with elevated ...
    ... lead to less controversial method of treating diseases , , ... they,ve reprogrammed human skin cells into ones with the ... that could aid in treating many diseases while sidestepping ... to become every cell type found in the human ...
    ... Inc.,(Nasdaq: NXXI ), the developer and marketer ... Iceland Health(R) brands that,help consumers manage blood sugar ... joint pain, today announced financial,results for the second ... 2007., The Company reported a 43% increase ...
    ... Feb. 11 Lincare Holdings,Inc. (Nasdaq: LNCR ), ... delivered to patients in the home, today announced,financial results ... 2007., For the quarter ended December 31, 2007, ... $368.1 million for the fourth quarter of,2006. The Company ...
    Cached Medicine News:Health News:UCSD research team identifies novel anticancer drug from the sea 2Health News:Swine flu monitoring needed for farm workers, study says 2Health News:Montefiore Lead Poisoning Prevention ProgramNamed One of Three State Regional Resource Centers 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 2Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 3Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 4Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 5Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 6Health News:Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results 7Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 2Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 3Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 4Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 5Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 6Health News:Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2007 Financial Results 7
    (Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
    (Date:11/26/2014)... , Nov. 25, 2014  Array ... today announced that its Chief Executive Officer, ... the following upcoming conferences.  The public is ... webcasts on the Array BioPharma website:  ... 3, 2014Time:1:30 p.m.  Eastern Time Location: Palace ...
    (Date:11/26/2014)... and LONDON , Nov. 25, 2014 /PRNewswire/ ... AZN ) today announced that AMAGINE-2 TM , ... brodalumab in more than 1,800 patients with moderate-to-severe plaque psoriasis, ... (ustekinumab) and placebo at week 12. Brodalumab 210 mg ... were each shown to be superior to Stelara on the ...
    Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
    ... SAN FRANCISCO, Calif., May 16, 2012  Rigel Pharmaceuticals, Inc., ... franchise by focusing on two innovative, comprehensive treatment alternatives ... an inhaled SYK inhibitor, will be entering a Phase ... moderate asthmatic patients. The other, R256, an inhaled IL13 ...
    ... May 15, 2012   OphthaliX (OTCBB: OPLI) today ... ended March 31, 2012. OphthaliX is an advanced clinical-stage ... treatment of ophthalmic disorders.  Our drug, CF101 (known generically ... indications: dry eye syndrome; glaucoma and uveitis. We are ...
    Cached Medicine Technology:Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 2Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 3Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease 4OphthaliX Reports First Quarter 2012 Financial Results 2OphthaliX Reports First Quarter 2012 Financial Results 3
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    Duraloc acetabular cup system....
    ... acetabular cup system has been designed to ... tri-spiked and cluster hole configurations. The objective ... micromotion on three primary modes: Tilt, migration ... features result in initial and long-term fixation. ...
    Biopro rimmed acetabular is manufactured from titanium and is porous coated on the outside of its shell. The rimmed acetabular accommodates a polyethylene inert....
    Medicine Products: